Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Altimmune, Inc. (NASDAQ:ALT) also announced on the same day that it intends to use the net proceeds from the offering for working capital, general company needs, and getting ready for its next Phase 3 ...
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the best biotech stocks on our list is Altimmune, Inc. TheFly reported on January 27 that Barclays initiated ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
He coined "vibe coding." Now, he sees a "phase shift" in software engineering. Andrej Karpathy is one of AI's guiding figures. He was a founding member of OpenAI and later served as Tesla's director ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results